Nebentan

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206017

CAS#: 403604-85-3

Description: Nebentan, also known as YM598, is a n orally active synthetic substituted phenylethenesulfonamide. As a selective endothelin A receptor antagonist, YM598 inhibits endothelin-mediated mechanisms involved in tumor cell growth and progression, angiogenesis, and metastasis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-09-28. Prices are subject to change without notice.

Nebentan is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 206017
Name: Nebentan
CAS#: 403604-85-3
Chemical Formula: C24H21N5O5S
Exact Mass: 491.12634
Molecular Weight: 491.51904
Elemental Analysis: C, 58.65; H, 4.31; N, 14.25; O, 16.28; S, 6.52


Synonym: YM598, YM 598, YM598, Nebentan.

IUPAC/Chemical Name: (E)-N-(6-methoxy-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)-2-phenylethenesulfonamide

InChi Key: LONWRQOYFPYMQD-DTQAZKPQSA-N

InChi Code: InChI=1S/C24H21N5O5S/c1-32-18-11-6-7-12-19(18)34-20-21(29-35(30,31)16-13-17-9-4-3-5-10-17)27-23(28-24(20)33-2)22-25-14-8-15-26-22/h3-16H,1-2H3,(H,27,28,29)/b16-13+

SMILES Code: O=S(/C=C/C1=CC=CC=C1)(NC2=NC(C3=NC=CC=N3)=NC(OC)=C2OC4=CC=CC=C4OC)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


Additional Information

  
 
 
 


References

1: Ukai M, Yuyama H, Fujimori A, Koakutsu A, Sanagi M, Ohtake A, Sato S, Sudoh K, Sasamata M, Miyata K. In vitro and in vivo effects of endothelin-1 and YM598, a selective endothelin ET A receptor antagonist, on the lower urinary tract. Eur J Pharmacol. 2008 Feb 12;580(3):394-400. Epub 2007 Nov 23. PubMed PMID: 18078923.

2: Someya A, Yuyama H, Fujimori A, Ukai M, Fukushima S, Sasamata M. Effect of YM598, a selective endothelin ETA receptor antagonist, on endothelin-1-induced bone formation. Eur J Pharmacol. 2006 Aug 14;543(1-3):14-20. Epub 2006 Jun 27. PubMed PMID: 16843458.

3: Yuyama H, Fujimori A, Sanagi M, Koakutsu A, Noguchi Y, Sudoh K, Sasamata M, Miyata K. A novel and selective endothelin ET(A) receptor antagonist YM598 prevents the development of chronic hypoxia-induced pulmonary hypertension in rats. Vascul Pharmacol. 2005 Jun;43(1):40-6. Epub 2005 Apr 21. PubMed PMID: 15975532.

4: Yuyama H, Koakutsu A, Fujiyasu N, Fujimori A, Sato S, Shibasaki K, Tanaka S, Sudoh K, Sasamata M, Miyata K. Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S479-82. PubMed PMID: 15838353.

5: Sugimoto K, Fujimori A, Yuyama H, Tahara A, Fujimura A. Renal protective effect of YM598, a selective endothelin type A receptor antagonist. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S451-4. PubMed PMID: 15838346.

6: Sudoh K, Yuyama H, Noguchi Y, Fujimori A, Ukai M, Ohtake A, Sato S, Sasamata M, Miyata K. Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S390-3. PubMed PMID: 15838329.

7: Fujimori A, Miyauchi T, Sakai S, Yuyama H, Iemitsu M, Sanagi M, Sudoh K, Goto K, Shikama H, Yamaguchi I. YM598, an orally active ET(A) receptor antagonist, ameliorates the progression of cardiopulmonary changes and both-side heart failure in rats with cor pulmonale and myocardial infarction. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S354-7. PubMed PMID: 15838319.

8: Yuyama H, Noguchi Y, Fujimori A, Ukai M, Fujiyasu N, Ohtake A, Sato S, Sudoh K, Sasamata M, Miyata K. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol. 2004 Sep 13;498(1-3):171-7. PubMed PMID: 15363992.

9: Yuyama H, Fujimori A, Sanagi M, Koakutsu A, Sudoh K, Sasamata M, Miyata K. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Eur J Pharmacol. 2004 Aug 2;496(1-3):129-39. PubMed PMID: 15288584.

10: Yuyama H, Sonoda R, Shibasaki K, Fujimori A, Sudoh K, Sasamata M, Miyata K. Effect of single oral administration of YM598, a novel selective endothelin ETA receptor antagonist, on blood pressure in normotensive and hypertensive rats. Vascul Pharmacol. 2004 Feb;41(1):27-34. PubMed PMID: 15135329.